I think the big mistake here is assuming the AAIC presentation is about Anavex. I believe this was more about Ariana, especially since Mohammed Afshar was the main presenter. The presentation is more a capabilty of what KEM analysis can weed out, and allow researchers to focus on. Anavex happens to be a strong partner and their data makes for good analysis. I'm not convinced theres much more to this than that. Gut microbia makes for possible biomarker.
HUH? Talk about Flashbacks. After years of the expression "Shathead" or "Shat for brains" being used for descriptive purpose this is perhaps in fact meaningful AD clinical expressions or diagnostic information. For example, if all these "shatheads" hanging around here all day w/nothing positive or constructive to say were to be given this title as a clinical expression then they were actually being positively diagnosed. HUH.
The presentation has a lot of info to decipher. One theme I see is they say if this happens -
"Disturbances along the Brain-Gut-Microbiota Axis including the CNS contribute to the pathogenesis of Alzheimer’s disease.
Alterations in the gut microbiota composition induce increased permeability of the gut barrier and immune activation leading to systemic inflammation which in turn may impair the blood-brain barrier and promote neuroinflammation, neural injury, and ultimately neurodegeneration.
The gut microbiota is known to upregulate local and systemic inflammation from pathogenic bacteria and synthesis of proinflammatory cytokines"
Then this could happen:
"The S1R agonist ANAVEX®2-73 could potentially normalize neuroinflammatory processes by several different mechanisms:
I do like the idea that they(Anavex and others) are looking into more of the why parts of neuro diseases.
Does this info fit into what another company says is their goal?
"Today's opening of G2D2 reaffirms our relentless pursuit to discover innovative medicines that may someday offer a complete treatment regimen that is preventative, restorative and regenerative to help address the devastation patients and families experience living with these debilitating diseases."